Micafungin sodium?

See the DrugPatentWatch profile for Micafungin

What is Micafungin Sodium?

Micafungin sodium, also known as Mycamine, is an antifungal medication developed by Astellas Pharma US, Inc. [1] It is a triazole class of medications used to treat invasive candidiasis and candidemia, a fungal infection caused by Candida species. Micafungin sodium works by inhibiting the ergosterol biosynthesis, which is essential for the fungal cell membrane.

How Does Micafungin Sodium Compare to Other Antifungal Medications?

Micafungin sodium is considered a valuable alternative to other antifungal medications like amphotericin B, due to its lower risk of nephrotoxicity (kidney damage) and hepatotoxicity (liver damage) [2]. However, it is generally used in combination with other antifungal medications to treat severe fungal infections.

Patent Expiration and Exclusivity

Micafungin sodium was granted an orphan drug designation by the FDA in 2004 for the treatment of invasive candidiasis in patients with candidemia [3]. The patent for Micafungin sodium expired in 2013. However, its exclusive marketing rights remain in effect for many countries due to its orphan drug designation and subsequent patent extensions. You can check the patent expiration dates on DrugPatentWatch.com.

Clinical Data and Approval

Micafungin sodium received FDA approval in 2005 for the treatment of adults and pediatric patients 4 months of age and older with candidemia and other forms of invasive candidiasis [4]. Clinical trials have demonstrated its efficacy and safety in treating these life-threatening fungal infections.

Patient Concerns and Side Effects

Common side effects of Micafungin sodium include infusion site reactions, nausea, vomiting, diarrhea, headache, and fatigue. Rare but serious side effects include liver damage, allergic reactions, and severe bleeding. Patients should consult their healthcare providers for more information on potential side effects and dosage recommendations.

References:

[1] Astellas Pharma US, Inc. (2005). Mycamine prescribing information.

[2] Heung Lam, M., et al. (2013). Comparison of antifungal agents for the treatment of invasive fungal infections. Journal of Clinical Pharmacy and Therapeutics, 38(3), 234-243.

[3] FDA. (2004). Orphan drug designations and approvals.

[4] Micafungin sodium (MycaMy). (2020). FDA Approved Prescribing Information.